Effect of Alfacalcidol on Anemia in Renal Failure Patients | ||||
| Suez Canal University Medical Journal | ||||
| Article 3, Volume 14, Issue 1, March 2011, Page 11-15 PDF (118.97 K) | ||||
| Document Type: Original Article | ||||
| DOI: 10.21608/scumj.2011.56014 | ||||
 View on SCiNiTO | ||||
| Authors | ||||
| Dalal El-Ellisy* 1; Mohamed M Ewais2; El-Sayed E El-Awady1; Gamal A Tawfik3 | ||||
| 1Department of Pharmacology & Toxicology, Faculty of Pharmacy, Suez Canal University, Egypt. | ||||
| 2Department of Pharmacology & Toxicology, Faculty of Medicine, Suez Canal University, Egypt. | ||||
| 3Department of Internal Medicine, Faculty of Medicine, Suez Canal University, Egypt | ||||
| Abstract | ||||
| Background: Anemia is a major feature of chronic kidney disease (CKD). Additionally, secondary hyperparathyroidism (SHPT) has been associated with anemia in uremic patients. Administration of active vitamin D metabolites like alfacalcidol is established for PTH suppression and may also play a role in hematopoiesis. Aim:To investigate the effect of alfacalcidol on anemia and SHPT with end stage renal failure patients underwent hemodialysis. Subjects and Methods: In the present study 17 anemic patients over 15years, with serum level of PTH greater than 500pg/ml. The study was carried out by means of data collection and analysis of serum parathyroid hormone (PTH) and hemoglobin (Hb) levels in these patients. Results: Low serum PTH levels were detected in uremic patients treated with alfacalcidol. Also, in these patients, Hb levels increased. Serum PTH and Hb levels were inversely correlated. Conclusions: High-dose alfacalcidol can decrease serum PTH levels and elevate Hb level in uremic patients showing considerable resistance to Epoetin. | ||||
| Keywords | ||||
| Anemia; PTH; alfacalcidol; ESRD; uremic patients; SHPT | ||||
|
Statistics Article View: 154 PDF Download: 402 |
||||
